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CYP3A5 metabolizes endogenous substrates and ~30% of prescription drugs. The
CYP3A5 gene contains an active CYP3A5*1 allele, and a non-functional version, the
CYP3A5*3 (rs776746), with consequences for drug therapeutic responses and side
effects. Both CYP3A5*1 and *3 have been associated with hypertension. The frequency of
CYP3A5*3 varies between populations of different ancestries, with Europeans having the
highest allele frequency (> 90%). Given the importance ofCYP3A5*3 in drug response and
hypertension development, the aim of the present study was to evaluate the frequency of
this polymorphism and its association with hypertension in vulnerable indigenous
populations in Mexico. A total of 372 subjects were recruited from eight ethnic groups
in Northwest Mexico. Systolic (SBP), diastolic (DBP), and median (MBP) blood pressures
as well as body mass index (BMI) were measured. Ancestry was evaluated through STR
analysis, and the CYP3A5*1/*3 polymorphisms were identified using real-time PCR with
TaqMan® probes. Higher frequencies of CYP3A5*1 and *3 were observed in groups with
higher (>90%) and lower (<90%) Amerindian ancestry, respectively. The CYP3A5*3/*3
genotype was more frequent in indigenous women with higher SBP and DBP values. On
the other hand, the *1 allele showed a protective effect against both high SBP (OR, 0.38;
95% CI, 0.17–0.83, p = 0.001) and DBP (OR 0.38, 95% CI 0.18–0.81, p = 0.007) in
women. This association remained significant after adjusting for BMI and age for diastolic
(OR, 0.38; 95% CI, 0.17–0.84, p = 0.011) and systolic BP (OR, 0.33; 95% CI, 0.15–0.76,
p = 0.005) BP levels in women. Thus, the frequency of CYP3A5*3 varies between groups
and seems to depend on ancestry, and CYP3A5*1 decreases the risk of hypertension in
Mexican indigenous women. This population analysis of CYP3A5*1/*3 has profound
implications not only for the susceptibility to diseases, such as hypertension, but also forin.org May 2020 | Volume 11 | Article 6381
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side effects.Keywords: CYP3A5, polymorphisms, Amerindian, Mexican, hypertension, ancestryINTRODUCTION
The CYP3A5 enzyme is a member of the cytochrome P450
(CYP) 3A subfamily, which metabolizes ~30% of the drugs used
in clinical practice (Zanger and Schwab, 2013). CYP3A5 protein
is expressed mainly in the liver (Zhang et al., 2016) with an
extrahepatic expression predominantly at the level of the renal
proximal tubule (Givens et al., 2003; Bolbrinker et al., 2012). In
kidney cells, CYP3A5 catalyzes the 6b-hydroxylation of
corticosterone and cortisol (Grogan et al., 1990; Schuetz et al.,
1992), increasing renal retention of Na+ and influencing blood
pressure (Watlington et al., 1992; Ghosh et al., 1995). The renal
expression of CYP3A5 is variable (Haehner et al., 1996) and
depends mainly on a non-functional polymorphism in intron 3
called CYP3A5*3 (6986A > G, rs776746), which causes RNA
splicing, resulting in protein termination at amino acid 109
(Kuehl et al., 2001). The frequency of CYP3A5*3 varies
considerably across populations, with the highest frequencies
in Europeans (94%) and admixed Americans (80%), and the
lowest in Africans (18%) (Zhou et al., 2017). Thompson et al.
(2004) reported that the frequency of CYP3A5*3 shows an
unusual geographic distribution and increases significantly
with distance from the equator. This could be because the
functional reference allele CYP3A5*1 may confer a selective
advantage in dry weather by increasing Na+ and water
retention (Kuehl et al., 2001).
In several studies, CYP3A5 has been associated with
hypertension in humans, although the results have been
controversial, as evidenced by the review described by Bochud
et al. (2009) and other recent studies (Fisher et al., 2016; Li et al.,
2017). Ethnicity of study subjects may help explain these
inconsistencies, as it has been demonstrated that the
association of the CYP3A5*1 allele with higher blood pressure
occurs mainly in individuals of African descent, while in
Caucasians it has only been observed in older individuals.
In Mexico, seven million inhabitants speak an indigenous
language. In the northwest of the country, the main ethnic
groups are distributed in two well-defined geographical
regions. Five indigenous groups, the Coras, Huicholes,
Tepehuanos, Tarahumaras, and Mexicaneros inhabit the Sierra
Madre Occidental where the mean annual temperature is 19°C.
On the other hand, the Seris, Guarijıós, and Mayos are located in
semi-desert regions with a mean annual temperature of 30°C.
Currently, the distribution of the CYP3A5*3 polymorphism
in Mexican indigenous groups is unknown, and the association
of the CYP3A5 gene with hypertension has not been reported.
Thus, the aim of the present study was to determine the
frequency of CYP3A5 polymorphisms, and their association
with hypertension in Mexican Amerindians.in.org 2MATERIALS AND METHODS
Subjects
A total of 372 unrelated volunteers belonging to 8 different
indigenous ethnicities of Northwest Mexico were studied. The
sample included 94 Tepehuanos, 62 Huicholes, and 34
Mexicaneros from the state of Durango, 66 Tarahumaras from
the state of Chihuahua, 58 Coras from the state of Nayarit and 14
Seris, 14 Guarijıós, and 30 Mayos from the state of Sonora. The
study protocol was approved by the Ethics and Research
Committee of the Durango General Hospital of the Mexican
Health Ministry (Number 031/007). All subjects signed an
authorized informed consent form after being informed of the
nature of the study, in accordance with the Declaration
of Helsinki.
Participants were recruited from their respective communities
between 2010 and 2013. All individuals self-reported as
Amerindians, and their ancestry was confirmed by analyzing 15
short tandem repeat (STR) loci (Sosa-Macıás et al., 2013). Based on
the results, the populationwas divided into high (HAA, > 90%) and
low (LAA, < 90%) Amerindian ancestry. Medical histories and
physical examinations were obtained from adult men and non-
pregnant women to confirm that they were healthy. Volunteers
diagnosed with diabetes, hypertension (HT), or undergoing anti-
hypertensive treatment were excluded.
Measurements
Height and weight were measured in the standing position
without shoes using a standard stadimeter. Body mass index
(BMI) was calculated as weight (kg) divided by height (m²).
Overweight participants were classified based on a BMI ≥ 25
kg/m2.
Blood pressure (BP) was measured using a mercurial
sphygmomanometer in triplicate to obtain the mean value as
the final BP after the participant had been sitting for at least 5
min. A diagnosis of HT was defined as systolic blood pressure
(SBP) ≥ 140 mm Hg, diastolic blood pressure (DBP) ≥ 90 mm
Hg, and median arterial pressure (MAP) ≥ 105 mmHg, based on
the Seventh Report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (Jones and Hall, 2004).
Admixture Analysis
The analysis of 15 STRs was performed using the AmpFISTR®
Identifiler Kit (Applied Biosystems). The amplified PCR
products were analyzed using capillary electrophoresis in an
ABI PRISM® 3130 Genetic Analyzer, and genotypes were
obtained using allelic ladders provided by the kit and the
GeneMapper® software 3.1 (Applied Biosystems).May 2020 | Volume 11 | Article 638
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A total of 5 mL of peripheral blood was drawn from an
antecubital vein into a tube with EDTA and kept on ice during
transportation to the laboratory. Genomic DNA was extracted
using the QIAGEN Blood DNA Isolation Kit (QIAGEN, Hilden,
Germany), and evaluated for integrity and concentration
through 1% agarose electrophoresis and spectrophotometry,
respectively. Genotyping was performed with quantitative real-
time PCR using a TaqMan® assay in a StepOne equipment
(Applied Biosystems, Carlsbad, CA, USA). PCR amplification
was performed in a 20 mL final volume containing 20 ng of
template DNA, 1X TaqMan® Genotyping Master Mix (Applied
Biosystems), 1X specific TaqMan® probe, and water. Thermal
cycling conditions were as follows: an initial denaturation step of
10 min at 95°C, followed by 40 cycles of denaturation at 92°C for
15 s and annealing at 60°C for 1 min. Genotype identification
was carried out using allelic discrimination software (Applied
Biosystems). The TaqMan® probe used to recognize CYP3A5*3
(rs776746) was C_26201809_30. Genotypes were evaluated in
duplicate, and the results were confirmed through Sanger
sequencing in 40 randomized samples (~10% of the
total population).
Statistical Analyses
Anthropometric parameters in the Mexican-Amerindian
populations are presented as mean ± standard deviation, andFrontiers in Pharmacology | www.frontiersin.org 3comparisons were made using the Mann–Whitney U test. The
inter-ethnic CYP3A5 allele and genotype frequencies were
compared using the c2 and Fisher’s exact tests. The CYP3A5 allele
and genotype frequencies between normotensive and hypertensive
subjects were performed using the Mann–WhitneyU and Pearson’s
c2 tests. Statistical analyses were carried out using the statistical
package SPSS® version 25 for Windows (SPSS Inc., Chicago IL).
Hardy–Weinberg equilibrium (HWE) was calculated using the c2
goodness-of-fit test. The association between polymorphisms and
HT was determined using multivariate logistic regression analysis,
and the model was adjusted for age and BMI. These analyses were
carried out using the SNPStats program (Solé et al., 2006). Statistical
significance was established with a 95% confidence interval (CI) and
a p value < 0.05.RESULTS
A total of 372 Amerindian volunteers were enrolled, 120 (32.3%)
men and 252 (67.7%) women. The anthropometric parameters
for all populations investigated are summarized in Table 1.
There were significant differences in BMI, SBP, DBP, and MAP
between populations, which were higher in the Seris, Guarijios,
and Mayos than in the other groups.
Previously, we studied 15 STRs to estimate non-Amerindian

















Age (years) 55.9 ± 13.9 58.1 ± 14.5 45.1 ± 18.2 42.8 ± 13.2 41.5 ± 13.9 40.1 ± 19.0 47.4 ± 20.9 36.6 ± 14.6
BMI (kg/m2) 27.3 ± 4.9* 27.6 ± 9.8* 27.8 ± 6.7* 24.1 ± 4.7 24.4 ± 3.9 23.5 ± 4.7 25.7 ± 5.3 22.3 ± 5.2
Systolic BP (mm
Hg)
142.1 ± 27.8* 145.6 ± 19.6* 128.8 ± 20.1* 122.3 ± 19.0 117.1 ± 16.2 112.5 ± 21.2 120.6 ± 15.3 105.1 ± 16.4
Diastolic BP (mm
Hg)
92.1 ± 12.5* 92.1 ± 7.8* 83.6 ± 11.7* 78.9 ± 9.4 74.7 ± 10.2 71.6 ± 12.4 78.4 ± 11.0 68.9 ± 11.6
MAP (mm Hg) 108.8 ± 16.4* 110.0 ± 10.4* 98.7 ± 14.0* 93.4 ± 12.0 88.8 ± 11.7 85.2 ± 14.6 92.5 ± 11.8 81 ± 12.8May 2020 | Volume 1Data are expressed as mean ± standard deviation.
*Mann–Whitney U test.
MAP, median arterial pressure; BMI, body mass index; BP, blood pressure.TABLE 2 | CYP3A5*3 allele and genotypic frequencies among Mexican-Amerindian populations.
Population N CYP3A5*3
Ancestry (%)1 Allele frequencies (%) Genotypic frequencies (%) HWE
Amerindian European *1 (A) *3 (G) *1/*1 (A/A) *1/*3 (G/A) *3/*3 (G/G) p value¤
Tepehuanos 94 96.4 3.1 28.7 71.3 12.8 31.9 55.3 0.04
Huicholes 62 96.3 3.1 11.3 88.7 3.2 16.1 80.6 0.16
Mexicaneros 34 94.5 4.3 57.4 42.6 38.2 38.2 23.5 0.29
Coras 58 93.9 4.7 33.6 66.4 15.5 36.2 48.3 0.15
Tarahumaras 66 92.1 7.0 28.0 72.0 10.6 34.8 54.5 0.36
Seris 14 88.0 11.0 3.6 96.4 0 7.14 92.9 1.00
Guarijıós 14 81.6 16.8 7.1 92.9 0 14.3 85.7 1.00
Mayos 30 65.6 32.6 3.3 96.7 0 6.7 93.3 1.001 | AHWE, Hardy–Weinberg equilibrium; ¤c2 goodness-of-fit statistic. 1Sosa-Macıás et al., 2013.rticle 638
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observed in the Mayo group, while the Tepehuano group had the
highest indigenous component (Table 2). The distribution of
CYP3A5 genotypes deviates from HWE only in the Tepehuano
group. The wild-type allele CYP3A5*1 was most frequent in the
groups with higher indigenous ancestry: Mexicaneros (57.4%),
Coras (33.6%), Tepehuanos (28.7%), Tarahumaras (28%), and
Huicholes (11.3%). The highest frequencies of CYP3A5*3 were
observed in the Mayos (96.7%), Seris (96.4%), and Guarijıós
(92.9%) groups with higher European admixture. In these
groups, no homozygote status (CYP3A5*1/*1) was detected,
and the *1/*3 genotype frequency was lower than in groups
with higher indigenous components. Higher homozygosity for
the allele CYP3A5*3 was found in the Mayos (93.3%), Seris
(92.9%), Guarijıós (85.7%), and Huicholes (80.6%).
In order to determine relationships between blood pressure
levels and CYP3A5*3 allele and genotypic frequencies, an
analysis of the total population was carried out (Table 3). The
frequency of allele *3 was significantly higher (84%) in
Amerindians with diastolic BPs ≥ 90 mm Hg (p < 0.001). The
*1/*3 genotype was the most frequent in subjects with diastolic
BPs <90 mm Hg (29.8%), but only occurred in 17.8% of subjects
with diastolic BPs ≥90 mm Hg (p = 0.04). A higher percentage of
subjects with genotype *3/*3 was observed in the groups with the
highest diastolic (75.3%) and systolic (74.6%) BP figures (p values
0.01 and 0.02, respectively). There were no significant differences
in the allele and genotype frequencies of CYP3A5*3 in terms of
MAP values.
Gender analysis revealed significant differences only in
Amerindian women (Table 4). The frequency of allele
CYP3A5*3 was significantly higher in women with diastolic BPs
≥90mmHg and systolic BPs ≥140 mmHg than in the groups with
lower BP values (p = 0.01). In women with diastolic BPs <90 mm
Hg the *1/*3 genotype was significantly more frequent (29.3%)
than in females with diastolic BPs ≥90 mm Hg (14.9%) (p = 0.04).
The *3/*3 genotype frequency was higher in the groups with
higher diastolic (78.7%) and systolic (79.1%) BPs than in groups
with lower figures (58.5% and 58.9% respectively, p = 0.01).Frontiers in Pharmacology | www.frontiersin.org 4Table 5 shows the results of the logistic regression analysis.
After a crude and adjusted analysis under a dominant
inheritance model, a significant negative association was found
between CYP3A5*1 and high diastolic, systolic, and MAP values
in the whole population. A similar association was also observed
in the female groups, but not in terms of MAP values. The
analysis of male groups did not reveal any association.DISCUSSION
Our results show that the frequency of the CYP3A5*3 allele is
higher in indigenous groups with lower Amerindian ancestry,
while CYP3A5*1 decreases the risk of HT in Mexican
indigenous women.
CYP3A5 metabolizes a great variety of drugs and endogenous
compounds that regulate physiological processes including blood
pressure. The expression of CYP3A5 depends in part on
polymorphisms whose frequencies vary in different populations.
In the current study, the highest frequencies of CYP3A5*3
were observed in the three groups with the LAA (92.9 – 96.7%),
which is similar to those reported for Europeans, Asians, and
admixed Americans (> 90%) (Zhou et al., 2017). In the
Tepehuano group exclusively, the observed genotype
distributions deviated from HWE, likely resulting from the
geographic isolation and endogamy present in the indigenous
community from which most subjects were recruited. It is worth
mentioning that the total number of participants from the
different ethnic groups depended on both the number of
inhabitants per community as well as the number of
individuals who agreed to participate in the study.
On the other hand, the observed frequencies of CYP3A5*1 in
the five groups with HAA and the groups with LAA ranged from
11.3% to 57.4% in the former, and 3% to 7% in the latter. Table 6
shows the frequencies of CYP3A5*1 in each population. The
frequencies in the groups with HAA coincide with those
observed in Mexican Amerindians (30.3%) and Mestizos
(18.9%) (Gonzalez-Covarrubias et al., 2019), and with thoseTABLE 3 | CYP3A5*3 allele and genotype frequencies in normotensive and hypertensive Mexican-Amerindian population.
Diastolic BP, mm Hg p value Systolic BP, mm Hg p value
<90 ≥90 <140 ≥140
n=299 n=73 n=307 n=65
BP 71.6 ± 9.5 94.6 ± 6.3 0.000 110.5 ± 14.2 151.8 ± 14.2 0.000
Age (years) 39.9 ± 15.6 53.9 ± 15.3 0.000 39.5 ± 15.4 57.4 ± 13.2 0.000
BMI (kg/m2) 23.8 ± 4.2 26.8 ± 5.6 0.000 24.1 ± 4.5 25.5 ± 5.5 0.043
Alleles
*1 (A) 165 (27.6) 23 (15.8) 0.002 165 (26.9) 23 (17.7) 0.029
*3 (G) 433 (72.4) 123 (84.3) 449 (73.1) 107 (82.3)
Genotypes
*1/*1 (A/A) 38 (12.7) 5 (6.8) 0.160 38 (12.4) 5 (7.7) 0.283
*1/*3 (A/G) 89 (29.8) 13 (17.8) 0.040 89 (29.1) 13 (20.0) 0.140
*3/*3 (G/G) 172 (57.5) 55 (75.3) 0.005 180 (58.6) 47 (72.3) 0.040May 2020 | Volume 11 | Arn (%). BP, blood pressure; BMI, body mass index.
Mann–Whitney U test, Pearson c2, p < 0.005 in bold.ticle 638
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(~30%). Meanwhile, the groups with LAA had similar
frequencies as Caucasians (5%) (Hustert et al., 2001). Roy et al.
(2005) evaluated Caucasian Canadians and reported frequencies
of 7% for CYP3A5*1, an identical frequency to that found in our
group with LAA. The frequency of CYP3A5*1 in FrenchFrontiers in Pharmacology | www.frontiersin.org 5Caucasians, Gabonese, and Tunisian subjects was 0%, 5%, and
3%, respectively (Quaranta et al., 2006). In the Iranian
population, the frequency of CYP3A5*1 was 8% (Azarpira
et al., 2011), which is similar to that observed in Jordanians
(7%) (Yousef et al., 2012). The low frequency in both populations
was similar to that in the LAA groups in the present study. The
evaluation of CYP3A5*1 in the Mexican Mestizo population
revealed a frequency of 9% (Vargas-Alarcón et al., 2014),
almost the same as that in the LAA Amerindian groups with
the highest levels of European admixture (Seris, Guarijios,
and Mayos).
It is well known that the functional allele CYP3A5*1 is
involved in sodium reabsorption and influences blood pressure
(Eap et al., 2007). In 2003, Givens et al. demonstrated that the
heterozygous genotype CYP3A5*1/*3 gave rise to a higher
expression of the CYP3A5 enzyme in the kidneys compared to
the inactive CYP3A5*3 homozygous form. The same studyTABLE 5 | Association of CYP3A5*1 and hypertension.
Population/variable OR (95% CI) p value
Whole cohort/DBP crude analysis 0.44 (0.25–0.79) 0.004
Whole cohort/DBP adjustment age, BMI 0.44 (0.23–0.83) 0.009
Whole cohort/SBP crude analysis 0.54 (0.30–0.98) 0.036
Whole cohort/SBP adjustment age, BMI 0.51 (0.27–0.97) 0.034
Whole cohort/MAP crude analysis 0.51 (0.27–0.96) 0.029
Whole cohort/MAP adjustment age, BMI 0.49 (0.24–0.97) 0.033
Women/DBP crude analysis 0.38 (0.18–0.81) 0.007
Women/DBP adjustment age/BMI 0.38 (0.17–0.84) 0.011
Women/SBP crude analysis 0.38 (0.17–0.83) 0.001
Women/SBP adjustment age/BMI 0.33 (0.15–0.76) 0.005
Women/MAP crude analysis 0.50 (0.23–1.12) 0.082
Women/MAP adjustment age/BMI 0.46 (0.19–1.11) 0.071
Men/DBP crude analysis 0.55 (0.22–1.39) 0.200
Men/DBP adjustment age/BMI 0.51 (0.18–1.43) 0.190
Men/SBP crude analysis 0.71 (0.26–1.94) 0.500
Men/SBP adjustment age/BMI 0.75 (0.25–2.27) 0.610
Men/MAP crude analysis 0.50 (0.18–1.40) 0.170
Men/MAP adjustment age/BMI 0.48 (0.16–1.47) 0.190OR, odds ratio; DBP, diastolic blood pressure; SBP, systolic blood pressure;
MAP, median arterial pressure; BMI, body mass index. p < 0.05 in bold.TABLE 4 | CYP3A5*3 allele and genotype frequencies in normotensive and hypertensive women and men.
Diastolic BP, mm Hg p value Systolic BP, mm Hg p value
<90 ≥90 <140 ≥140
Women n = 205 n = 47 n = 209 n = 43
BP 71.4 ± 9.4 93.8 ± 5.6 0.000 109.7 ± 13.9 148 ± 9.2 0.000
Age (years) 38.8 ± 14.8 51.4 ± 15.2 0.000 37.9 ± 14.1 56.9 ± 13.1 0.000
BMI (kg/m2) 24.3 ± 4.3 27.5 ± 5.8 0.000 24.7 ± 4.5 25.7 ± 5.9 0.373
Alleles
*1 (A) 110 (26.8) 13 (13.8) 0.009 112 (26.8) 11 (12.8) 0.011
*3 (G) 300 (73.2) 81 (86.2) 306 (73.2) 75 (87.2)
Genotypes
*1/*1 (A/A) 25 (12.2) 3 (6.4) 0.253 26 (12.4) 2 (4.7) 0.185
*1/*3 (A/G) 60 (29.3) 7 (14.9) 0.044 60 (28.7) 7 (16.3) 0.093
*3/*3 (G/G) 120 (58.5) 37 (78.7) 0.010 123 (58.9) 34 (79.1) 0.013
Men n=94 n=26 n=98 n=22
BP 72 ± 9.7 96 ± 7.5 0.000 112.2 ± 14.8 159.3 ± 18.8 0.000
Age (years) 42.4 ± 17 58.5 ± 14.9 0.000 43.2 ± 17.4 58.4 ± 13.5 0.000
BMI (kg/m2) 22.7 ± 4 25.5 ± 5.1 0.006 22.9± 4.2 25.2 ± 4.5 0.007
Alleles
*1 (A) 55 (29.3) 10 (19.2) 0.150 53 (27) 12 (27.3) 0.257
*3 (G) 133 (70.7) 42 (80.8) 143 (73) 32 (72.7)
Genotypes
*1/*1 (A/A) 13 (13.8) 2 (7.7) 0.519 12 (12.24) 3 (13.6) 1.00
*1/*3 (A/G) 29 (30.9) 6 (23.1) 0.440 29 (29.6) 6 (27.3) 0.653
*3/*3 (G/G) 52 (55.3) 18 (69.2) 0.203 57 (58.2) 13 (59.1) 0.508May 2020 | Volume 11 | Arn (%). BP, blood pressure; BMI, body mass index.




Indigenous HAA 11.3 - 57 This study
Indigenous LAA 3 - 7 This study
Mexican Amerindian 30.3 Gonzalez-Covarrubias et al., 2019
Mexican Mestizo 18.9 Gonzalez-Covarrubias et al., 2019
MXL 23 Data from 1000 Genomes
CEU 4 Data from 1000 Genomes
YRI 83 Data from 1000 Genomes
CHB 31 Data from 1000 GenomesHAA, high Amerindian ancestry; LAA, low Amerindian ancestry.ticle 638
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women with the CYP3A5*1/CYP3A5*1 genotype (Givens et al.,
2003). Similar results have been found in other studies. In 2005,
Ho et al. compared hypertensive vs. normotensive Caucasian and
black subjects and found higher baseline DBP and SBP in the
black group with CYP3A5*1/*1 or CYP3A5*1/*3 genotypes. The
same results were observed after saline infusion and furosemide
administration, but these results were not observed in white
subjects (Ho et al., 2005). In African descendants, an age-
dependent significant increase in BP values was observed only
in those carrying the CYP3A5*1 allele (Bochud et al., 2006).
In Japanese men, the homozygous genotype *1/*1 was
observed in subjects with high DBP, while no differences
between genotypes were observed for SBP (Zhang et al., 2010).
Conversely, in the present study the frequency of the
homozygous genotype CYP3A5*1 was higher in normotensive
subjects, although these results were not significant. A similar
result was demonstrated in Caucasian women and men with low
SBP values carrying the homozygous CYP3A5*1 genotype,
although such an effect was not observed for DBP (Kreutz
et al., 2005). In contrast, a German Caucasian population
showed no association between high SBP or DBP and the
CYP3A5*1 allele (Lieb et al., 2006).
On the other hand, in this study, the frequency of CYP3A5*1/
*3 was significantly higher in women with lower DBP, while the
CYP3A5*3/*3 genotype was over-represented in women with
higher DBP and SBP. Such differences were not found in men.
The distributions of genotypes in the present study agree with
those reported by Fromm et al. (2005), who found higher SBP in
young Caucasian men with CYP3A5*3/*3, compared with
subjects carrying CYP3A5*1/*3 genotype, suggesting a *3 allele
dose-effect which could be associated with high systolic blood
pressure (Fromm et al., 2005).
The functional allele CYP3A5*1 contributes to salt avidity
(sodium retention) and hence HT. It is more frequent in
populations closer to the equator and is considered an
ancestral allele in African populations before diaspora
(Thompson et al., 2004). We observed a protective effect of the
*1 allele in women against high diastolic and systolic BP, which
remained after adjusting for BMI and age [diastolic (OR 0.38,
95% CI 0.17–0.84, p = 0.011) and systolic BP (OR 0.33, 95% CI
0.15–0.76, p = 0.005) BP]. Conversely, no association was found
in the male group, presumably because of the lower number of
samples in this group (Table 5). In this study, we observed that
populations with HAA showed the highest frequencies of the *1
allele and were the most normotensive groups. These
populations are settled in mountainous communities with low
environmental salt availability, so the presence of the *1 allele is
beneficial, similar to what may have occurred in ancient
populations in Africa. This phenomenon could explain the
apparently paradoxical observation. On the other hand, the
observed association in women could be the result of
the higher number of women in this study.
Scarce reports exist about the prevalence of HT in indigenous
Mexican populations. In 2008, Rodrıǵuez-Moran et al. in the
search for cardiovascular risk factors, evaluated two ethnicFrontiers in Pharmacology | www.frontiersin.org 6groups from Northwestern Mexico (Tepehuanos and Yaquis),
who presented with HT in 3.3% and 6.3% of the study subjects,
respectively (Rodrıǵuez-Morán et al., 2008). The same authors
showed in a follow up study an increase in the prevalence of HT
from 1.7% in 1996 to 3.5% in 2006 in Tepehuano’s communities
(Rodrı ́guez-Morán et al., 2009). These data reveal that
indigenous groups are adopting westernized habits, which is
supported by the three groups in our study with LAA, who
presented the highest values of BP and were located in more
accessible and warmer communities with higher salt intakes. In
this case, the presence of *3 was not sufficient to eliminate the
high amount of salt, giving rise to the high BP values observed in
these groups.
The distribution of *1 and *3 alleles in these populations and
the influence of environmental factors, such as the use of
traditional herbal remedies, can have repercussions in drug
responses, making the evaluation of genetic profiles in
indigenous groups more relevant.
This is the case in the Huichol group, which has the highest
frequency of homozygous *3/*3 among the groups with the
highest indigenous ancestry, which can be explained by the
geographical differences between these groups. Huichols
inhabit a region with little water availability, which could be an
environmental pressure to maintain the *3 allele, promoting
water retention without the development of hypertension. In
addition, it is a community with little interaction with other
groups, which has allowed them to maintain their habits and
customs and could explain why they are among the groups with
normal blood pressure.
Some limitations of this study deserve mention. Only one
blood pressure measurement was performed. Because of the
geographic isolation of these studied groups, a high rate of
endogamy cannot be ignored. There were a high number of
women compared to men. No measures of dietary salt content or
urine salt elimination were performed. CYP3A5-interacting
genes such as AGT were not evaluated.
To the best of our knowledge, this is the first study to evaluate
the distribution of CYP3A5 *1 and *3 alleles and its association
with HT in a Mexican indigenous population confirmed by
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